In conclusion, this study demonstrated that the Ab3‐8 anti‐ASCT2 mAb inhibits the tumor growth of colon cancer cells with KRAS mutation by inhibiting glutamine uptake. The gene discussed is SLC1A5; the disease is malignant colon neoplasm.